Last reviewed · How we verify
Nifedipine Extended-Release Tablets
At a glance
| Generic name | Nifedipine Extended-Release Tablets |
|---|---|
| Sponsor | Duke University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease Subjects (PHASE2)
- Persistent Postpartum Hypertension Pilot Trial (PHASE4)
- Bioequivalence of Extended Release Nifedipine Tablets in Healthy Chinese Subjects (PHASE1)
- Drug Interaction With Proton Pump Inhibitors for Nifedipine ER Tablets (PHASE1)
- Black Education and Treatment of Hypertension (BEAT HTN) (PHASE4)
- A Relative Bioavailability Study of 60 mg Nifedipine ER Tablets Under Non-fasting Conditions (PHASE1)
- A Relative Bioavailability Study of 60 mg Nifedipine Extended Release Tablets Under Fasting Conditions (PHASE1)
- Nifedipine Bioavailability Study With Oral Single Doses Under Fasting and Fed Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nifedipine Extended-Release Tablets CI brief — competitive landscape report
- Nifedipine Extended-Release Tablets updates RSS · CI watch RSS
- Duke University portfolio CI